Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr

The company reported lifetime high EBIDTA of Rs. 250 crores

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22

Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr

US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore

Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr

The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

Labindia partners with Hamilton Laboratory to launch ‘Labindia Hamilton’

Product deliveries scheduled in Q3 of 2023

Lincoln Pharmaceuticals posts FY23 PAT at Rs. 72.90 Cr

For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year

Mandaviya addresses 76th World Health Assembly

The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world

JB Pharma records revenue growth of 22% to Rs. 762 Cr

Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23

Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development

Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing